NASDAQ$SKIN
SkinHealth Systems Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported third quarter net sales of $78.8 million and improved profitability due to strategic initiatives.
BeautyHealth reported Q3 2024 net sales of $78.8 million, a decrease of 19.1% compared to Q3 2023. However, the company saw improved profitability with an increase in gross margin and adjusted EBITDA, driven by operational excellence initiatives and disciplined expense management. The company also revised its full year net sales guidance lower and improved its adjusted EBITDA guidance.
- Net sales were $78.8 million, a decrease of (19.1)% compared to Q3 2023, due to lower delivery systems net sales.
- Gross margin was 51.6% compared to (12.9)% in Q3 2023, primarily due to the absence of charges associated with the Syndeo Program in 2023 and lower inventory related charges.
- Net loss was $(18.3) million compared to net loss of $(73.8) million in Q3 2023, primarily due to costs associated with the Syndeo Program in 2023.
- Adjusted EBITDA was $8.1 million compared to $9.1 million in Q3 2023, primarily due to lower net sales offset by higher gross margin and lower operational spend.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$78.8M
Revenue by segment
Beauty Health · $97.4M total across 2 segments · Q3 2023
- Delivery Systems$51M+3.9%52.4%
- Consumables$46.4M+16.9%47.6%
Forward guidance
The Company revised its full year net sales guidance lower due to continued pressure on delivery systems sales and improved its adjusted EBITDA guidance to reflect stronger profitability in the third quarter.
Tailwinds
- Improved Q3 2024 gross margin performance
- Reduction in operational spend
- Assumes no material deterioration in general market conditions
- Excludes any unannounced acquisitions
- Excludes any unannounced dispositions or financings.
Headwinds
- Revised full-year net sales guidance reflects continued downward pressure on delivery systems sales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro